| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 143 | 2025 | 169 | 44.460 |
Why?
|
| Arthroplasty, Replacement, Hip | 75 | 2026 | 117 | 27.810 |
Why?
|
| Arthroplasty, Replacement, Knee | 79 | 2026 | 155 | 26.500 |
Why?
|
| Arthritis, Rheumatoid | 93 | 2026 | 284 | 24.610 |
Why?
|
| Antirheumatic Agents | 71 | 2026 | 123 | 20.300 |
Why?
|
| Rheumatology | 77 | 2025 | 130 | 17.550 |
Why?
|
| Gout Suppressants | 64 | 2025 | 75 | 16.630 |
Why?
|
| Lupus Erythematosus, Systemic | 27 | 2026 | 229 | 14.130 |
Why?
|
| Allopurinol | 43 | 2025 | 79 | 12.600 |
Why?
|
| Osteoarthritis | 32 | 2025 | 105 | 11.060 |
Why?
|
| Osteoarthritis, Hip | 28 | 2025 | 62 | 10.500 |
Why?
|
| Osteoarthritis, Knee | 37 | 2025 | 282 | 9.900 |
Why?
|
| Patient Participation | 25 | 2026 | 254 | 9.240 |
Why?
|
| Medicare | 37 | 2024 | 442 | 9.090 |
Why?
|
| Uric Acid | 48 | 2025 | 110 | 9.000 |
Why?
|
| Rheumatic Diseases | 37 | 2024 | 78 | 8.960 |
Why?
|
| Decision Support Techniques | 13 | 2026 | 293 | 7.890 |
Why?
|
| Biological Products | 26 | 2024 | 145 | 7.460 |
Why?
|
| Hospitalization | 37 | 2025 | 1950 | 7.260 |
Why?
|
| Aged | 243 | 2026 | 21025 | 6.680 |
Why?
|
| United States | 158 | 2026 | 12072 | 6.220 |
Why?
|
| Arthroplasty, Replacement | 16 | 2023 | 26 | 6.030 |
Why?
|
| Length of Stay | 34 | 2025 | 1421 | 5.970 |
Why?
|
| Febuxostat | 19 | 2021 | 21 | 5.770 |
Why?
|
| Humans | 561 | 2026 | 131163 | 5.740 |
Why?
|
| Middle Aged | 238 | 2026 | 28601 | 5.670 |
Why?
|
| Hyperuricemia | 17 | 2022 | 39 | 5.670 |
Why?
|
| Quality of Life | 57 | 2025 | 2082 | 5.280 |
Why?
|
| Aged, 80 and over | 107 | 2026 | 6797 | 5.180 |
Why?
|
| Male | 310 | 2026 | 64957 | 5.030 |
Why?
|
| Patient Acceptance of Health Care | 17 | 2023 | 512 | 5.010 |
Why?
|
| Hospital Mortality | 26 | 2025 | 1064 | 4.990 |
Why?
|
| Female | 318 | 2026 | 70963 | 4.900 |
Why?
|
| Postoperative Complications | 36 | 2025 | 3147 | 4.680 |
Why?
|
| Comorbidity | 55 | 2025 | 1595 | 4.600 |
Why?
|
| Immunosuppressive Agents | 12 | 2026 | 663 | 4.100 |
Why?
|
| Healthcare Disparities | 12 | 2025 | 523 | 3.660 |
Why?
|
| Risk Factors | 95 | 2025 | 11074 | 3.650 |
Why?
|
| Cohort Studies | 65 | 2025 | 5063 | 3.620 |
Why?
|
| Treatment Outcome | 120 | 2026 | 12936 | 3.490 |
Why?
|
| Clinical Trials as Topic | 34 | 2023 | 1129 | 3.400 |
Why?
|
| Reoperation | 29 | 2020 | 818 | 3.400 |
Why?
|
| Lupus Nephritis | 7 | 2019 | 43 | 3.370 |
Why?
|
| Surgeons | 8 | 2023 | 289 | 3.350 |
Why?
|
| Pain | 21 | 2023 | 450 | 3.250 |
Why?
|
| Knee Joint | 14 | 2022 | 177 | 3.250 |
Why?
|
| Shoulder Joint | 10 | 2015 | 32 | 3.230 |
Why?
|
| Veterans | 24 | 2025 | 1763 | 3.220 |
Why?
|
| Randomized Controlled Trials as Topic | 36 | 2024 | 1267 | 3.120 |
Why?
|
| Pain Measurement | 35 | 2021 | 353 | 3.100 |
Why?
|
| Activities of Daily Living | 16 | 2019 | 386 | 2.970 |
Why?
|
| Medication Adherence | 11 | 2024 | 338 | 2.960 |
Why?
|
| Incidence | 54 | 2026 | 3360 | 2.840 |
Why?
|
| Patient Reported Outcome Measures | 13 | 2026 | 222 | 2.820 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2023 | 29 | 2.810 |
Why?
|
| Adult | 117 | 2026 | 31282 | 2.730 |
Why?
|
| Myocardial Infarction | 10 | 2025 | 999 | 2.690 |
Why?
|
| Rural Population | 5 | 2025 | 276 | 2.620 |
Why?
|
| Databases, Factual | 28 | 2025 | 1240 | 2.600 |
Why?
|
| Periprosthetic Fractures | 7 | 2013 | 11 | 2.600 |
Why?
|
| Cardiovascular Diseases | 14 | 2025 | 2121 | 2.470 |
Why?
|
| Registries | 25 | 2024 | 1634 | 2.350 |
Why?
|
| Hospital Charges | 11 | 2024 | 70 | 2.320 |
Why?
|
| Decision Making | 15 | 2026 | 726 | 2.250 |
Why?
|
| Health Status | 18 | 2025 | 378 | 2.250 |
Why?
|
| Glucocorticoids | 12 | 2022 | 348 | 2.240 |
Why?
|
| Sex Factors | 30 | 2025 | 1356 | 2.220 |
Why?
|
| Chondrocalcinosis | 12 | 2026 | 16 | 2.200 |
Why?
|
| Practice Guidelines as Topic | 23 | 2020 | 1295 | 2.140 |
Why?
|
| Surveys and Questionnaires | 45 | 2026 | 4066 | 2.110 |
Why?
|
| Methotrexate | 13 | 2022 | 350 | 2.090 |
Why?
|
| United States Department of Veterans Affairs | 17 | 2026 | 729 | 2.050 |
Why?
|
| Recovery of Function | 18 | 2017 | 449 | 2.030 |
Why?
|
| Arthralgia | 11 | 2021 | 78 | 1.970 |
Why?
|
| Patient Readmission | 8 | 2025 | 442 | 1.960 |
Why?
|
| Pyrroles | 7 | 2018 | 188 | 1.960 |
Why?
|
| Vasculitis | 3 | 2021 | 47 | 1.960 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 496 | 1.930 |
Why?
|
| Arthroplasty, Replacement, Ankle | 4 | 2019 | 4 | 1.930 |
Why?
|
| Piperidines | 7 | 2018 | 223 | 1.910 |
Why?
|
| Medicaid | 7 | 2021 | 268 | 1.900 |
Why?
|
| Severity of Illness Index | 40 | 2026 | 3061 | 1.820 |
Why?
|
| Arthritis, Psoriatic | 9 | 2022 | 15 | 1.800 |
Why?
|
| Humeral Head | 5 | 2012 | 5 | 1.790 |
Why?
|
| Arthritis | 6 | 2024 | 85 | 1.780 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 1378 | 1.780 |
Why?
|
| Urban Population | 4 | 2025 | 287 | 1.780 |
Why?
|
| Inpatients | 10 | 2025 | 562 | 1.780 |
Why?
|
| Delivery of Health Care | 11 | 2022 | 689 | 1.770 |
Why?
|
| Pyrimidines | 8 | 2023 | 446 | 1.760 |
Why?
|
| Scleroderma, Systemic | 4 | 2020 | 118 | 1.740 |
Why?
|
| Physician-Patient Relations | 7 | 2022 | 441 | 1.730 |
Why?
|
| Proportional Hazards Models | 21 | 2020 | 1410 | 1.720 |
Why?
|
| Time Factors | 36 | 2026 | 6196 | 1.720 |
Why?
|
| Giant Cell Arteritis | 3 | 2021 | 49 | 1.720 |
Why?
|
| Self Report | 9 | 2021 | 554 | 1.720 |
Why?
|
| Prospective Studies | 36 | 2025 | 6459 | 1.690 |
Why?
|
| Communicable Diseases | 4 | 2021 | 155 | 1.680 |
Why?
|
| Antibodies, Monoclonal | 14 | 2020 | 981 | 1.670 |
Why?
|
| Arthroplasty | 6 | 2021 | 17 | 1.670 |
Why?
|
| Plant Extracts | 4 | 2020 | 130 | 1.660 |
Why?
|
| Sjogren's Syndrome | 3 | 2020 | 109 | 1.660 |
Why?
|
| Hip Joint | 5 | 2016 | 48 | 1.650 |
Why?
|
| Retrospective Studies | 60 | 2026 | 17753 | 1.650 |
Why?
|
| Age Factors | 28 | 2020 | 2825 | 1.630 |
Why?
|
| Dementia | 5 | 2018 | 436 | 1.600 |
Why?
|
| Patient Satisfaction | 12 | 2025 | 464 | 1.590 |
Why?
|
| Telemedicine | 5 | 2025 | 526 | 1.580 |
Why?
|
| Qualitative Research | 8 | 2025 | 730 | 1.570 |
Why?
|
| Arthritis, Gouty | 5 | 2019 | 7 | 1.570 |
Why?
|
| Fibromyalgia | 3 | 2024 | 20 | 1.570 |
Why?
|
| Elective Surgical Procedures | 8 | 2025 | 162 | 1.550 |
Why?
|
| Risk Assessment | 26 | 2023 | 3711 | 1.540 |
Why?
|
| Logistic Models | 19 | 2021 | 1797 | 1.500 |
Why?
|
| Arthritis, Juvenile | 4 | 2024 | 45 | 1.480 |
Why?
|
| Spondylarthritis | 4 | 2020 | 8 | 1.450 |
Why?
|
| Hypertension | 10 | 2022 | 1356 | 1.440 |
Why?
|
| Low Back Pain | 3 | 2022 | 42 | 1.440 |
Why?
|
| Disease Management | 7 | 2020 | 558 | 1.410 |
Why?
|
| Myositis | 7 | 2025 | 84 | 1.390 |
Why?
|
| Patient Discharge | 9 | 2025 | 514 | 1.390 |
Why?
|
| Patient Education as Topic | 7 | 2020 | 464 | 1.380 |
Why?
|
| Cross-Sectional Studies | 24 | 2026 | 3829 | 1.340 |
Why?
|
| Polymyalgia Rheumatica | 2 | 2021 | 2 | 1.310 |
Why?
|
| Follow-Up Studies | 28 | 2022 | 5196 | 1.300 |
Why?
|
| Consensus | 22 | 2025 | 512 | 1.300 |
Why?
|
| Hypothyroidism | 2 | 2023 | 71 | 1.290 |
Why?
|
| Anti-Anxiety Agents | 2 | 2021 | 70 | 1.280 |
Why?
|
| Income | 4 | 2025 | 138 | 1.280 |
Why?
|
| Shoulder Pain | 4 | 2011 | 21 | 1.280 |
Why?
|
| Diabetes Mellitus | 9 | 2024 | 889 | 1.240 |
Why?
|
| Colchicine | 7 | 2025 | 40 | 1.230 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1224 | 1.230 |
Why?
|
| Prosthesis-Related Infections | 4 | 2019 | 197 | 1.230 |
Why?
|
| Hallucinogens | 2 | 2021 | 67 | 1.210 |
Why?
|
| Cocaine | 2 | 2021 | 211 | 1.210 |
Why?
|
| Evidence-Based Medicine | 15 | 2018 | 645 | 1.200 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2016 | 333 | 1.180 |
Why?
|
| Chronic Pain | 7 | 2021 | 168 | 1.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2020 | 292 | 1.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2026 | 919 | 1.140 |
Why?
|
| Odds Ratio | 16 | 2019 | 1211 | 1.140 |
Why?
|
| Obesity | 10 | 2024 | 2426 | 1.100 |
Why?
|
| Osteonecrosis | 3 | 2023 | 15 | 1.100 |
Why?
|
| Alcoholism | 2 | 2021 | 244 | 1.100 |
Why?
|
| Rituximab | 9 | 2026 | 170 | 1.090 |
Why?
|
| Surgical Wound Infection | 7 | 2017 | 267 | 1.090 |
Why?
|
| Disability Evaluation | 10 | 2016 | 191 | 1.090 |
Why?
|
| Hemiarthroplasty | 3 | 2012 | 4 | 1.090 |
Why?
|
| Spondylitis, Ankylosing | 6 | 2017 | 13 | 1.060 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 354 | 1.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2021 | 570 | 1.040 |
Why?
|
| Sleep Wake Disorders | 3 | 2019 | 204 | 1.020 |
Why?
|
| Organizational Culture | 2 | 2025 | 95 | 1.020 |
Why?
|
| Hip Fractures | 2 | 2025 | 64 | 1.010 |
Why?
|
| Health Expenditures | 2 | 2024 | 136 | 1.010 |
Why?
|
| Attitude of Health Personnel | 5 | 2024 | 707 | 1.010 |
Why?
|
| Blood Transfusion | 4 | 2024 | 294 | 1.000 |
Why?
|
| Arthritis, Infectious | 2 | 2018 | 65 | 1.000 |
Why?
|
| Urinary Tract Infections | 3 | 2021 | 342 | 0.990 |
Why?
|
| Etanercept | 10 | 2020 | 44 | 0.980 |
Why?
|
| Cost of Illness | 7 | 2026 | 297 | 0.980 |
Why?
|
| Sepsis | 2 | 2021 | 493 | 0.970 |
Why?
|
| Health Surveys | 8 | 2019 | 261 | 0.960 |
Why?
|
| Sleep | 3 | 2019 | 381 | 0.960 |
Why?
|
| Diabetes Complications | 3 | 2018 | 197 | 0.960 |
Why?
|
| Orthopedic Surgeons | 4 | 2020 | 14 | 0.950 |
Why?
|
| Global Burden of Disease | 7 | 2026 | 37 | 0.930 |
Why?
|
| Botulinum Toxins | 4 | 2012 | 113 | 0.920 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2024 | 853 | 0.920 |
Why?
|
| Sex Distribution | 13 | 2022 | 318 | 0.920 |
Why?
|
| Drug Therapy, Combination | 12 | 2022 | 1173 | 0.900 |
Why?
|
| Global Health | 16 | 2025 | 626 | 0.900 |
Why?
|
| Delphi Technique | 12 | 2025 | 283 | 0.890 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 314 | 0.880 |
Why?
|
| Arthroplasty, Replacement, Elbow | 2 | 2015 | 3 | 0.880 |
Why?
|
| Minnesota | 11 | 2016 | 178 | 0.880 |
Why?
|
| Research | 4 | 2014 | 264 | 0.870 |
Why?
|
| Population Surveillance | 3 | 2019 | 396 | 0.870 |
Why?
|
| Health Services | 4 | 2019 | 69 | 0.870 |
Why?
|
| Prognosis | 20 | 2021 | 4886 | 0.860 |
Why?
|
| Body Mass Index | 9 | 2024 | 1717 | 0.850 |
Why?
|
| Drug Monitoring | 4 | 2020 | 292 | 0.840 |
Why?
|
| Age Distribution | 13 | 2021 | 422 | 0.840 |
Why?
|
| Resilience, Psychological | 1 | 2025 | 84 | 0.840 |
Why?
|
| Rheumatologists | 2 | 2021 | 7 | 0.840 |
Why?
|
| Knee Prosthesis | 3 | 2013 | 20 | 0.830 |
Why?
|
| Primary Health Care | 5 | 2022 | 775 | 0.830 |
Why?
|
| Ambulatory Care | 2 | 2025 | 401 | 0.820 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2019 | 639 | 0.820 |
Why?
|
| Joint Prosthesis | 3 | 2012 | 15 | 0.810 |
Why?
|
| Teratogens | 1 | 2024 | 68 | 0.810 |
Why?
|
| Health Status Disparities | 3 | 2020 | 282 | 0.810 |
Why?
|
| Reproducibility of Results | 20 | 2026 | 2904 | 0.810 |
Why?
|
| Health Equity | 7 | 2020 | 78 | 0.810 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 69 | 0.800 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 111 | 0.800 |
Why?
|
| Abatacept | 9 | 2019 | 21 | 0.780 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2010 | 130 | 0.780 |
Why?
|
| Range of Motion, Articular | 6 | 2017 | 90 | 0.770 |
Why?
|
| Immunoconjugates | 5 | 2014 | 41 | 0.770 |
Why?
|
| Prosthesis Failure | 6 | 2013 | 159 | 0.770 |
Why?
|
| Genetic Loci | 2 | 2022 | 353 | 0.770 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 2 | 2020 | 14 | 0.750 |
Why?
|
| Thiazoles | 3 | 2014 | 113 | 0.750 |
Why?
|
| Personal Satisfaction | 2 | 2020 | 105 | 0.750 |
Why?
|
| Musculoskeletal Diseases | 6 | 2023 | 57 | 0.750 |
Why?
|
| Patient-Centered Care | 4 | 2024 | 236 | 0.750 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2022 | 6 | 0.740 |
Why?
|
| Chronic Disease | 17 | 2025 | 1246 | 0.740 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 35 | 0.730 |
Why?
|
| Uveitis | 2 | 2022 | 36 | 0.730 |
Why?
|
| Tai Ji | 2 | 2019 | 8 | 0.730 |
Why?
|
| Health Services Accessibility | 6 | 2020 | 712 | 0.720 |
Why?
|
| Stroke | 5 | 2019 | 1061 | 0.720 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 72 | 0.720 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2020 | 23 | 0.720 |
Why?
|
| Penile Implantation | 1 | 2022 | 25 | 0.720 |
Why?
|
| Rectal Fistula | 1 | 2022 | 4 | 0.710 |
Why?
|
| Gracilis Muscle | 1 | 2022 | 4 | 0.710 |
Why?
|
| Symptom Flare Up | 7 | 2021 | 25 | 0.710 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2015 | 73 | 0.710 |
Why?
|
| Physicians | 5 | 2022 | 635 | 0.710 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 633 | 0.710 |
Why?
|
| Elbow | 1 | 2021 | 8 | 0.710 |
Why?
|
| Urinary Fistula | 1 | 2022 | 14 | 0.710 |
Why?
|
| Kidney Diseases | 2 | 2017 | 477 | 0.710 |
Why?
|
| Urethral Diseases | 1 | 2022 | 16 | 0.710 |
Why?
|
| Hospitals, Veterans | 6 | 2019 | 336 | 0.700 |
Why?
|
| Penile Prosthesis | 1 | 2022 | 41 | 0.700 |
Why?
|
| Depression | 9 | 2018 | 1320 | 0.700 |
Why?
|
| Analgesics | 3 | 2021 | 120 | 0.690 |
Why?
|
| Infliximab | 8 | 2018 | 61 | 0.680 |
Why?
|
| Inflammation | 7 | 2022 | 1489 | 0.680 |
Why?
|
| Peptic Ulcer | 2 | 2012 | 151 | 0.670 |
Why?
|
| Research Design | 15 | 2021 | 716 | 0.670 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 5 | 2016 | 55 | 0.670 |
Why?
|
| Forecasting | 8 | 2025 | 351 | 0.670 |
Why?
|
| Databases as Topic | 2 | 2013 | 73 | 0.670 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 705 | 0.660 |
Why?
|
| Young Adult | 22 | 2026 | 10103 | 0.650 |
Why?
|
| Diet Therapy | 2 | 2020 | 40 | 0.650 |
Why?
|
| Cannabis | 1 | 2021 | 50 | 0.650 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 52 | 0.650 |
Why?
|
| Diagnostic Techniques and Procedures | 3 | 2019 | 32 | 0.650 |
Why?
|
| Hearing Loss | 2 | 2023 | 204 | 0.650 |
Why?
|
| Health Care Costs | 3 | 2016 | 407 | 0.650 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 184 | 0.640 |
Why?
|
| Ultrasonography | 3 | 2021 | 943 | 0.640 |
Why?
|
| Prunus domestica | 1 | 2020 | 1 | 0.640 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 738 | 0.640 |
Why?
|
| Attitude to Health | 3 | 2020 | 247 | 0.630 |
Why?
|
| Adalimumab | 7 | 2022 | 22 | 0.620 |
Why?
|
| Polymyositis | 1 | 2020 | 12 | 0.620 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2016 | 650 | 0.620 |
Why?
|
| Calcium Pyrophosphate | 7 | 2026 | 9 | 0.620 |
Why?
|
| Predictive Value of Tests | 12 | 2016 | 2304 | 0.610 |
Why?
|
| Social Perception | 1 | 2020 | 52 | 0.610 |
Why?
|
| Ankle Joint | 3 | 2015 | 33 | 0.610 |
Why?
|
| Culturally Competent Care | 2 | 2020 | 50 | 0.610 |
Why?
|
| Finches | 1 | 2019 | 6 | 0.600 |
Why?
|
| Erectile Dysfunction | 1 | 2022 | 184 | 0.600 |
Why?
|
| Hospital Costs | 4 | 2025 | 188 | 0.600 |
Why?
|
| Radiography | 9 | 2018 | 743 | 0.600 |
Why?
|
| Knee Injuries | 1 | 2019 | 36 | 0.600 |
Why?
|
| Dyslipidemias | 1 | 2022 | 256 | 0.600 |
Why?
|
| Feasibility Studies | 8 | 2025 | 824 | 0.600 |
Why?
|
| Pneumonia | 3 | 2021 | 341 | 0.600 |
Why?
|
| Quality Indicators, Health Care | 3 | 2018 | 240 | 0.590 |
Why?
|
| Smoking | 4 | 2011 | 932 | 0.590 |
Why?
|
| Longitudinal Studies | 8 | 2025 | 1490 | 0.590 |
Why?
|
| Phytotherapy | 2 | 2020 | 48 | 0.590 |
Why?
|
| Analgesics, Opioid | 4 | 2026 | 546 | 0.580 |
Why?
|
| Hospitals, County | 1 | 2019 | 22 | 0.580 |
Why?
|
| Dermatitis, Atopic | 4 | 2023 | 56 | 0.580 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 237 | 0.580 |
Why?
|
| Coronary Disease | 4 | 2021 | 624 | 0.570 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2019 | 71 | 0.570 |
Why?
|
| Congresses as Topic | 2 | 2017 | 184 | 0.570 |
Why?
|
| Hospitals, Low-Volume | 3 | 2015 | 36 | 0.570 |
Why?
|
| Anti-Dyskinesia Agents | 2 | 2009 | 40 | 0.560 |
Why?
|
| Heart Diseases | 3 | 2012 | 499 | 0.560 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 101 | 0.560 |
Why?
|
| Hospitals, High-Volume | 3 | 2015 | 44 | 0.560 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 51 | 0.560 |
Why?
|
| Vulnerable Populations | 5 | 2017 | 151 | 0.560 |
Why?
|
| Symptom Assessment | 4 | 2020 | 110 | 0.550 |
Why?
|
| Prevalence | 16 | 2026 | 2701 | 0.540 |
Why?
|
| Sickness Impact Profile | 4 | 2011 | 38 | 0.530 |
Why?
|
| Electronic Health Records | 2 | 2025 | 844 | 0.530 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 398 | 0.520 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 89 | 0.520 |
Why?
|
| Spiro Compounds | 1 | 2017 | 12 | 0.520 |
Why?
|
| Triazoles | 4 | 2019 | 141 | 0.520 |
Why?
|
| Macular Degeneration | 1 | 2018 | 86 | 0.510 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 2065 | 0.510 |
Why?
|
| Quality of Health Care | 3 | 2010 | 413 | 0.510 |
Why?
|
| Patient Preference | 3 | 2020 | 151 | 0.510 |
Why?
|
| Sacroiliac Joint | 1 | 2017 | 5 | 0.510 |
Why?
|
| Furans | 1 | 2017 | 28 | 0.510 |
Why?
|
| Tobacco Use | 2 | 2023 | 29 | 0.510 |
Why?
|
| Joint Instability | 2 | 2016 | 55 | 0.510 |
Why?
|
| Propensity Score | 4 | 2020 | 271 | 0.500 |
Why?
|
| Substance P | 1 | 2017 | 31 | 0.500 |
Why?
|
| Back Pain | 1 | 2017 | 30 | 0.500 |
Why?
|
| Biomarkers | 13 | 2022 | 3385 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2024 | 1618 | 0.490 |
Why?
|
| Physical Fitness | 3 | 2016 | 93 | 0.490 |
Why?
|
| Health Resources | 1 | 2018 | 131 | 0.490 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 205 | 0.490 |
Why?
|
| Quality Improvement | 3 | 2019 | 722 | 0.480 |
Why?
|
| Health Status Indicators | 3 | 2019 | 111 | 0.480 |
Why?
|
| Chemokines | 1 | 2017 | 126 | 0.480 |
Why?
|
| Pessimism | 1 | 2016 | 5 | 0.480 |
Why?
|
| Fees and Charges | 1 | 2016 | 10 | 0.470 |
Why?
|
| Remission Induction | 7 | 2024 | 306 | 0.470 |
Why?
|
| Precision Medicine | 2 | 2017 | 388 | 0.470 |
Why?
|
| Tacrolimus | 1 | 2016 | 100 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 789 | 0.470 |
Why?
|
| Consumer Behavior | 1 | 2016 | 30 | 0.470 |
Why?
|
| Review Literature as Topic | 5 | 2017 | 55 | 0.470 |
Why?
|
| Quadriceps Muscle | 2 | 2016 | 16 | 0.470 |
Why?
|
| Office Visits | 1 | 2016 | 80 | 0.470 |
Why?
|
| Self Care | 1 | 2017 | 231 | 0.460 |
Why?
|
| Drug Substitution | 1 | 2015 | 27 | 0.460 |
Why?
|
| Mortality | 5 | 2021 | 264 | 0.460 |
Why?
|
| Complementary Therapies | 1 | 2016 | 45 | 0.460 |
Why?
|
| Prunus | 1 | 2015 | 1 | 0.450 |
Why?
|
| Tuberculosis | 4 | 2017 | 550 | 0.450 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2015 | 7 | 0.450 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2026 | 9 | 0.450 |
Why?
|
| Drug Therapy | 1 | 2015 | 85 | 0.450 |
Why?
|
| Shoulder | 1 | 2015 | 33 | 0.450 |
Why?
|
| Hospitals | 2 | 2024 | 435 | 0.450 |
Why?
|
| Postoperative Period | 7 | 2017 | 331 | 0.450 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 27 | 0.450 |
Why?
|
| Biological Factors | 1 | 2015 | 25 | 0.440 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 393 | 0.440 |
Why?
|
| Calcinosis | 3 | 2021 | 180 | 0.440 |
Why?
|
| Evidence-Based Practice | 6 | 2024 | 115 | 0.440 |
Why?
|
| Autoimmune Diseases | 4 | 2024 | 262 | 0.440 |
Why?
|
| Chondroitin Sulfates | 1 | 2015 | 14 | 0.440 |
Why?
|
| Depressive Disorder | 1 | 2018 | 460 | 0.440 |
Why?
|
| Dietary Supplements | 2 | 2016 | 448 | 0.440 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 127 | 0.430 |
Why?
|
| Patients | 4 | 2022 | 122 | 0.430 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 245 | 0.430 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 73 | 0.420 |
Why?
|
| Survival Rate | 7 | 2021 | 2114 | 0.420 |
Why?
|
| Heart Failure | 3 | 2025 | 2332 | 0.420 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 224 | 0.420 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 73 | 0.420 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 428 | 0.420 |
Why?
|
| International Classification of Diseases | 3 | 2015 | 95 | 0.420 |
Why?
|
| Quality-Adjusted Life Years | 9 | 2023 | 129 | 0.410 |
Why?
|
| Thioglycolates | 3 | 2019 | 12 | 0.410 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 195 | 0.410 |
Why?
|
| Knee Dislocation | 1 | 2013 | 2 | 0.410 |
Why?
|
| Osteolysis | 1 | 2013 | 9 | 0.410 |
Why?
|
| Placebos | 4 | 2021 | 223 | 0.400 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 326 | 0.400 |
Why?
|
| Folic Acid Antagonists | 1 | 2013 | 16 | 0.400 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2019 | 301 | 0.400 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1419 | 0.390 |
Why?
|
| Sensitivity and Specificity | 9 | 2021 | 2085 | 0.390 |
Why?
|
| Leucovorin | 1 | 2013 | 53 | 0.390 |
Why?
|
| Exercise | 3 | 2021 | 892 | 0.390 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 30 | 0.380 |
Why?
|
| Bariatric Surgery | 2 | 2017 | 154 | 0.380 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 482 | 0.380 |
Why?
|
| Pandemics | 5 | 2022 | 1118 | 0.380 |
Why?
|
| Health Personnel | 4 | 2021 | 541 | 0.380 |
Why?
|
| Immunologic Factors | 2 | 2012 | 190 | 0.380 |
Why?
|
| Neoplasms | 5 | 2017 | 3016 | 0.380 |
Why?
|
| Epidemiologic Methods | 5 | 2016 | 91 | 0.380 |
Why?
|
| Drug Eruptions | 1 | 2013 | 33 | 0.370 |
Why?
|
| Eczema | 2 | 2023 | 35 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 269 | 0.370 |
Why?
|
| Administrative Claims, Healthcare | 3 | 2017 | 17 | 0.370 |
Why?
|
| Regression Analysis | 4 | 2018 | 761 | 0.370 |
Why?
|
| Outpatients | 1 | 2014 | 262 | 0.360 |
Why?
|
| Weight Loss | 3 | 2024 | 538 | 0.360 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 12 | 0.360 |
Why?
|
| Spondylarthropathies | 2 | 2009 | 2 | 0.350 |
Why?
|
| Treatment Failure | 5 | 2017 | 351 | 0.350 |
Why?
|
| Thromboembolism | 2 | 2011 | 93 | 0.350 |
Why?
|
| Observational Studies as Topic | 4 | 2022 | 106 | 0.350 |
Why?
|
| Exercise Therapy | 3 | 2023 | 173 | 0.350 |
Why?
|
| Terminology as Topic | 2 | 2017 | 226 | 0.350 |
Why?
|
| Parkinson Disease | 1 | 2019 | 735 | 0.340 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 563 | 0.340 |
Why?
|
| Societies, Medical | 9 | 2021 | 798 | 0.340 |
Why?
|
| Pennsylvania | 3 | 2019 | 60 | 0.340 |
Why?
|
| Folic Acid | 1 | 2013 | 269 | 0.330 |
Why?
|
| Quality Assurance, Health Care | 3 | 2019 | 205 | 0.330 |
Why?
|
| Crystal Arthropathies | 2 | 2022 | 5 | 0.330 |
Why?
|
| Self-Help Devices | 1 | 2010 | 10 | 0.330 |
Why?
|
| Perioperative Care | 3 | 2017 | 217 | 0.330 |
Why?
|
| Role | 1 | 2010 | 27 | 0.320 |
Why?
|
| Bayes Theorem | 4 | 2021 | 311 | 0.320 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 227 | 0.320 |
Why?
|
| Drug Design | 3 | 2018 | 156 | 0.320 |
Why?
|
| Internet | 4 | 2019 | 420 | 0.320 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 146 | 0.320 |
Why?
|
| Insurance Claim Review | 3 | 2018 | 27 | 0.310 |
Why?
|
| Hypnotics and Sedatives | 2 | 2021 | 132 | 0.310 |
Why?
|
| Socioeconomic Factors | 7 | 2016 | 915 | 0.300 |
Why?
|
| Brassica napus | 2 | 2009 | 5 | 0.300 |
Why?
|
| Cluster Analysis | 3 | 2022 | 414 | 0.300 |
Why?
|
| Military Medicine | 3 | 2010 | 52 | 0.300 |
Why?
|
| Adolescent | 17 | 2026 | 20987 | 0.300 |
Why?
|
| Self Disclosure | 1 | 2009 | 28 | 0.300 |
Why?
|
| Algorithms | 4 | 2016 | 1680 | 0.300 |
Why?
|
| Light-Harvesting Protein Complexes | 1 | 2009 | 1 | 0.300 |
Why?
|
| Sample Size | 1 | 2009 | 84 | 0.300 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 78 | 0.300 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 16 | 0.300 |
Why?
|
| Injections, Intra-Articular | 4 | 2010 | 30 | 0.300 |
Why?
|
| Efficiency | 1 | 2010 | 74 | 0.300 |
Why?
|
| Health Literacy | 4 | 2020 | 77 | 0.300 |
Why?
|
| Xanthine Oxidase | 2 | 2022 | 39 | 0.300 |
Why?
|
| Premenopause | 1 | 2009 | 33 | 0.290 |
Why?
|
| Morbidity | 4 | 2020 | 256 | 0.280 |
Why?
|
| Plant Proteins | 1 | 2009 | 86 | 0.280 |
Why?
|
| Organizational Innovation | 2 | 2021 | 43 | 0.280 |
Why?
|
| Interviews as Topic | 3 | 2026 | 466 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 934 | 0.270 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2018 | 28 | 0.270 |
Why?
|
| Data Collection | 3 | 2022 | 370 | 0.270 |
Why?
|
| Life Expectancy | 4 | 2020 | 63 | 0.270 |
Why?
|
| Staphylococcus aureus | 1 | 2011 | 483 | 0.270 |
Why?
|
| Endpoint Determination | 2 | 2018 | 58 | 0.270 |
Why?
|
| Pilot Projects | 5 | 2017 | 1445 | 0.270 |
Why?
|
| Polyethylene Glycols | 3 | 2016 | 235 | 0.270 |
Why?
|
| Skin | 3 | 2024 | 545 | 0.260 |
Why?
|
| Erythrocytes | 3 | 2017 | 186 | 0.260 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 198 | 0.260 |
Why?
|
| Professional-Patient Relations | 2 | 2019 | 92 | 0.260 |
Why?
|
| Interleukin-17 | 2 | 2018 | 125 | 0.260 |
Why?
|
| Meta-Analysis as Topic | 4 | 2017 | 169 | 0.260 |
Why?
|
| Patient Acuity | 2 | 2017 | 66 | 0.260 |
Why?
|
| Pain Management | 3 | 2019 | 205 | 0.250 |
Why?
|
| Social Participation | 3 | 2016 | 13 | 0.250 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1626 | 0.250 |
Why?
|
| Anxiety | 4 | 2018 | 1014 | 0.250 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 571 | 0.250 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 345 | 0.250 |
Why?
|
| Reference Values | 4 | 2017 | 676 | 0.250 |
Why?
|
| Certolizumab Pegol | 2 | 2016 | 7 | 0.250 |
Why?
|
| Analysis of Variance | 3 | 2013 | 928 | 0.240 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 327 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2833 | 0.240 |
Why?
|
| Bone and Bones | 1 | 2009 | 308 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2023 | 711 | 0.240 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 731 | 0.240 |
Why?
|
| Bone Density | 1 | 2009 | 367 | 0.240 |
Why?
|
| Standard of Care | 2 | 2017 | 133 | 0.240 |
Why?
|
| Case-Control Studies | 5 | 2025 | 3359 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 216 | 0.230 |
Why?
|
| Headache Disorders | 1 | 2025 | 5 | 0.230 |
Why?
|
| Immunoglobulin G | 5 | 2015 | 786 | 0.230 |
Why?
|
| Freezing | 1 | 2005 | 27 | 0.230 |
Why?
|
| Photosynthesis | 1 | 2005 | 13 | 0.230 |
Why?
|
| Uricosuric Agents | 2 | 2020 | 5 | 0.230 |
Why?
|
| Health Care Surveys | 2 | 2021 | 276 | 0.230 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 732 | 0.230 |
Why?
|
| Utilization Review | 2 | 2016 | 39 | 0.230 |
Why?
|
| Guideline Adherence | 4 | 2015 | 387 | 0.220 |
Why?
|
| Smoking Cessation | 3 | 2018 | 191 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2017 | 195 | 0.220 |
Why?
|
| Disease Progression | 4 | 2017 | 2200 | 0.220 |
Why?
|
| Prosthesis Design | 2 | 2022 | 643 | 0.220 |
Why?
|
| Insurance, Health | 2 | 2018 | 146 | 0.220 |
Why?
|
| CELF Proteins | 1 | 2024 | 6 | 0.210 |
Why?
|
| Synovitis | 1 | 2004 | 24 | 0.210 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 179 | 0.210 |
Why?
|
| Overweight | 3 | 2017 | 387 | 0.210 |
Why?
|
| New Zealand | 2 | 2021 | 63 | 0.210 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 40 | 0.200 |
Why?
|
| Medical Records | 1 | 2004 | 174 | 0.200 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2023 | 19 | 0.200 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 258 | 0.200 |
Why?
|
| Contraception | 1 | 2024 | 61 | 0.200 |
Why?
|
| Communication | 2 | 2019 | 543 | 0.200 |
Why?
|
| Public Opinion | 2 | 2021 | 64 | 0.200 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 241 | 0.200 |
Why?
|
| Tinnitus | 1 | 2023 | 23 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2025 | 231 | 0.200 |
Why?
|
| Hearing Aids | 1 | 2023 | 30 | 0.200 |
Why?
|
| Escherichia coli | 1 | 2009 | 991 | 0.190 |
Why?
|
| Muscle Strength | 2 | 2016 | 77 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2026 | 210 | 0.190 |
Why?
|
| Emotions | 1 | 2025 | 350 | 0.190 |
Why?
|
| Synovial Fluid | 2 | 2020 | 15 | 0.190 |
Why?
|
| Acute Disease | 5 | 2025 | 1153 | 0.190 |
Why?
|
| Linear Models | 3 | 2016 | 688 | 0.190 |
Why?
|
| Cementation | 2 | 2012 | 4 | 0.180 |
Why?
|
| Models, Statistical | 3 | 2015 | 483 | 0.180 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2014 | 12 | 0.180 |
Why?
|
| Military Personnel | 1 | 2025 | 219 | 0.180 |
Why?
|
| United Kingdom | 1 | 2022 | 267 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 60 | 0.180 |
Why?
|
| Urate Oxidase | 2 | 2012 | 19 | 0.180 |
Why?
|
| Amphetamines | 1 | 2021 | 8 | 0.180 |
Why?
|
| International Cooperation | 3 | 2018 | 165 | 0.170 |
Why?
|
| Risk | 3 | 2018 | 726 | 0.170 |
Why?
|
| Public Health | 2 | 2016 | 269 | 0.170 |
Why?
|
| Organizations | 1 | 2021 | 17 | 0.170 |
Why?
|
| Amphetamine | 1 | 2021 | 12 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 1071 | 0.170 |
Why?
|
| Attitude to Computers | 1 | 2021 | 38 | 0.170 |
Why?
|
| Occupational Stress | 1 | 2021 | 14 | 0.170 |
Why?
|
| Myristates | 1 | 2021 | 3 | 0.170 |
Why?
|
| Cetrimonium Compounds | 1 | 2021 | 4 | 0.170 |
Why?
|
| Simethicone | 1 | 2021 | 2 | 0.170 |
Why?
|
| Stearic Acids | 1 | 2021 | 4 | 0.170 |
Why?
|
| Nicotinic Acids | 1 | 2021 | 8 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 294 | 0.170 |
Why?
|
| Child | 15 | 2026 | 26341 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2023 | 296 | 0.160 |
Why?
|
| Physical Therapists | 1 | 2020 | 7 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2021 | 100 | 0.160 |
Why?
|
| Capsules | 1 | 2020 | 22 | 0.160 |
Why?
|
| Australia | 1 | 2021 | 173 | 0.160 |
Why?
|
| Rotator Cuff Tear Arthropathy | 1 | 2020 | 2 | 0.160 |
Why?
|
| Rotator Cuff | 1 | 2020 | 8 | 0.160 |
Why?
|
| Diclofenac | 2 | 2017 | 6 | 0.160 |
Why?
|
| Bias | 1 | 2021 | 151 | 0.160 |
Why?
|
| Canada | 2 | 2012 | 327 | 0.160 |
Why?
|
| Sexism | 1 | 2020 | 44 | 0.160 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 211 | 0.160 |
Why?
|
| Workload | 1 | 2021 | 151 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2025 | 1833 | 0.160 |
Why?
|
| Cytokines | 2 | 2017 | 1339 | 0.160 |
Why?
|
| Psychometrics | 3 | 2014 | 678 | 0.150 |
Why?
|
| Drug Combinations | 1 | 2021 | 270 | 0.150 |
Why?
|
| Exercise Movement Techniques | 1 | 2019 | 3 | 0.150 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 13 | 0.150 |
Why?
|
| Myocardium | 1 | 2005 | 852 | 0.150 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 11 | 0.150 |
Why?
|
| Midwestern United States | 2 | 2009 | 16 | 0.150 |
Why?
|
| Crohn Disease | 1 | 2022 | 292 | 0.150 |
Why?
|
| Racism | 1 | 2020 | 56 | 0.150 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 317 | 0.150 |
Why?
|
| Patient Selection | 2 | 2015 | 729 | 0.150 |
Why?
|
| Vaccination | 2 | 2022 | 1060 | 0.150 |
Why?
|
| Arthritis, Reactive | 2 | 2009 | 3 | 0.150 |
Why?
|
| Pamphlets | 1 | 2019 | 21 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 143 | 0.150 |
Why?
|
| Los Angeles | 1 | 2019 | 17 | 0.150 |
Why?
|
| Patient Advocacy | 1 | 2019 | 60 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 821 | 0.150 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2019 | 32 | 0.150 |
Why?
|
| Harm Reduction | 1 | 2019 | 12 | 0.150 |
Why?
|
| Enthesopathy | 1 | 2018 | 1 | 0.150 |
Why?
|
| Ustekinumab | 1 | 2018 | 3 | 0.150 |
Why?
|
| Spondylitis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Interleukin-23 | 1 | 2018 | 16 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 558 | 0.140 |
Why?
|
| Hospitals, Community | 1 | 2019 | 51 | 0.140 |
Why?
|
| Epilepsy | 2 | 2017 | 876 | 0.140 |
Why?
|
| Azetidines | 1 | 2018 | 60 | 0.140 |
Why?
|
| Occupational Therapy | 1 | 2018 | 37 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 750 | 0.140 |
Why?
|
| Nurses | 1 | 2019 | 65 | 0.140 |
Why?
|
| Workflow | 1 | 2019 | 144 | 0.140 |
Why?
|
| Homicide | 1 | 2018 | 34 | 0.140 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 22 | 0.140 |
Why?
|
| Liposarcoma | 1 | 2018 | 24 | 0.140 |
Why?
|
| Interleukin-12 | 1 | 2018 | 125 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 165 | 0.140 |
Why?
|
| Child Mortality | 2 | 2017 | 22 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 131 | 0.140 |
Why?
|
| Purines | 1 | 2018 | 118 | 0.140 |
Why?
|
| Social Class | 1 | 2019 | 214 | 0.140 |
Why?
|
| Learning | 1 | 2021 | 356 | 0.130 |
Why?
|
| Creatinine | 2 | 2021 | 398 | 0.130 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 39 | 0.130 |
Why?
|
| Motivation | 2 | 2020 | 328 | 0.130 |
Why?
|
| Pyridines | 1 | 2019 | 255 | 0.130 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 13 | 0.130 |
Why?
|
| Firearms | 1 | 2018 | 59 | 0.130 |
Why?
|
| Choice Behavior | 1 | 2019 | 148 | 0.130 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 93 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 688 | 0.130 |
Why?
|
| Goals | 1 | 2018 | 126 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2021 | 1345 | 0.130 |
Why?
|
| Hospitals, University | 2 | 2015 | 103 | 0.130 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2017 | 29 | 0.130 |
Why?
|
| Macrophages, Peritoneal | 1 | 2017 | 38 | 0.130 |
Why?
|
| Adolescent Health | 1 | 2017 | 17 | 0.130 |
Why?
|
| Antigens | 1 | 2017 | 105 | 0.130 |
Why?
|
| Neck Pain | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 555 | 0.130 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 38 | 0.130 |
Why?
|
| Skin Transplantation | 1 | 2017 | 57 | 0.130 |
Why?
|
| Fatigue | 2 | 2024 | 191 | 0.130 |
Why?
|
| Wounds, Gunshot | 1 | 2018 | 148 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2024 | 951 | 0.130 |
Why?
|
| Free Radical Scavengers | 1 | 2017 | 54 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2021 | 562 | 0.120 |
Why?
|
| Cell Proliferation | 1 | 2024 | 2465 | 0.120 |
Why?
|
| Manitoba | 1 | 2016 | 3 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 2017 | 94 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2017 | 237 | 0.120 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 194 | 0.120 |
Why?
|
| Genomics | 1 | 2025 | 1621 | 0.120 |
Why?
|
| Sensation | 1 | 2016 | 47 | 0.120 |
Why?
|
| Biomechanical Phenomena | 2 | 2016 | 279 | 0.120 |
Why?
|
| Sheep | 1 | 2017 | 229 | 0.120 |
Why?
|
| Leadership | 1 | 2019 | 255 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 909 | 0.120 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2016 | 10 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 2016 | 24 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2017 | 132 | 0.120 |
Why?
|
| Polyethyleneimine | 1 | 2016 | 10 | 0.120 |
Why?
|
| Checklist | 1 | 2017 | 97 | 0.120 |
Why?
|
| Spleen | 1 | 2017 | 258 | 0.120 |
Why?
|
| Mental Health | 2 | 2017 | 378 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2021 | 536 | 0.120 |
Why?
|
| Weight-Bearing | 1 | 2016 | 49 | 0.120 |
Why?
|
| Rifampin | 1 | 2017 | 128 | 0.120 |
Why?
|
| Child Health | 1 | 2017 | 72 | 0.120 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2016 | 65 | 0.120 |
Why?
|
| Psychotic Disorders | 1 | 2017 | 146 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2016 | 90 | 0.120 |
Why?
|
| Protective Factors | 1 | 2016 | 91 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 123 | 0.120 |
Why?
|
| Software | 2 | 2019 | 733 | 0.120 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 17 | 0.120 |
Why?
|
| Health Transition | 1 | 2015 | 10 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2018 | 349 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 149 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2005 | 2406 | 0.110 |
Why?
|
| Aftercare | 1 | 2017 | 157 | 0.110 |
Why?
|
| Sarcoma | 1 | 2018 | 219 | 0.110 |
Why?
|
| Suicide | 1 | 2018 | 208 | 0.110 |
Why?
|
| Animals | 6 | 2024 | 33912 | 0.110 |
Why?
|
| Melanoma | 1 | 2022 | 931 | 0.110 |
Why?
|
| Massachusetts | 1 | 2015 | 122 | 0.110 |
Why?
|
| Policy Making | 1 | 2015 | 63 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 327 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2007 | 304 | 0.110 |
Why?
|
| Life Style | 1 | 2018 | 456 | 0.110 |
Why?
|
| Organic Anion Transporters | 1 | 2015 | 23 | 0.110 |
Why?
|
| Focus Groups | 2 | 2014 | 239 | 0.110 |
Why?
|
| Gait | 1 | 2016 | 141 | 0.110 |
Why?
|
| TWEAK Receptor | 1 | 2015 | 3 | 0.110 |
Why?
|
| Glucosamine | 1 | 2015 | 11 | 0.110 |
Why?
|
| Renal Insufficiency | 2 | 2008 | 259 | 0.110 |
Why?
|
| Perception | 1 | 2016 | 231 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 2015 | 54 | 0.110 |
Why?
|
| Arkansas | 1 | 2015 | 53 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2012 | 272 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2015 | 75 | 0.110 |
Why?
|
| Writing | 1 | 2015 | 59 | 0.110 |
Why?
|
| Recurrence | 2 | 2025 | 1489 | 0.110 |
Why?
|
| Asthma | 1 | 2023 | 922 | 0.110 |
Why?
|
| Acculturation | 1 | 2015 | 62 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 978 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2019 | 564 | 0.110 |
Why?
|
| Flax | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genome, Plant | 1 | 2014 | 21 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1216 | 0.110 |
Why?
|
| Droughts | 1 | 2014 | 13 | 0.110 |
Why?
|
| Infant | 8 | 2026 | 13352 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 209 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 204 | 0.110 |
Why?
|
| Community Participation | 1 | 2014 | 42 | 0.100 |
Why?
|
| Hand | 1 | 2015 | 93 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2016 | 294 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 509 | 0.100 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2014 | 65 | 0.100 |
Why?
|
| Diet | 1 | 2021 | 1121 | 0.100 |
Why?
|
| Ankle | 1 | 2014 | 30 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 1 | 2014 | 225 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2014 | 62 | 0.100 |
Why?
|
| Mediterranean Region | 3 | 2018 | 8 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 143 | 0.100 |
Why?
|
| Gene Frequency | 1 | 2015 | 729 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2013 | 31 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 713 | 0.100 |
Why?
|
| Maternal Mortality | 1 | 2014 | 78 | 0.100 |
Why?
|
| Malaria | 1 | 2014 | 93 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2015 | 171 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2014 | 124 | 0.100 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 274 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2026 | 8635 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 185 | 0.100 |
Why?
|
| Child, Preschool | 8 | 2026 | 15110 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2017 | 552 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2016 | 320 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 194 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 157 | 0.100 |
Why?
|
| Illness Behavior | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2017 | 381 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 109 | 0.090 |
Why?
|
| Secondary Prevention | 2 | 2011 | 217 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 430 | 0.090 |
Why?
|
| Infant Mortality | 1 | 2014 | 183 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2015 | 749 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2013 | 79 | 0.090 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 8 | 0.090 |
Why?
|
| Mass Screening | 1 | 2018 | 822 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3763 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 305 | 0.090 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 25 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2015 | 298 | 0.090 |
Why?
|
| Tuberculin Test | 1 | 2013 | 120 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2012 | 26 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 259 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 56 | 0.090 |
Why?
|
| Education, Medical | 1 | 2016 | 293 | 0.090 |
Why?
|
| Europe | 3 | 2017 | 365 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2014 | 321 | 0.090 |
Why?
|
| Rotator Cuff Injuries | 1 | 2011 | 10 | 0.090 |
Why?
|
| Alabama | 1 | 2011 | 43 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 201 | 0.090 |
Why?
|
| Economics, Hospital | 1 | 2011 | 7 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 3436 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 86 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1272 | 0.090 |
Why?
|
| Cause of Death | 4 | 2017 | 506 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2013 | 194 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 20 | 0.090 |
Why?
|
| Probability | 2 | 2017 | 306 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 154 | 0.080 |
Why?
|
| Human Rights | 1 | 2011 | 25 | 0.080 |
Why?
|
| Health Services Research | 2 | 2010 | 180 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 158 | 0.080 |
Why?
|
| Bacterial Infections | 1 | 2014 | 327 | 0.080 |
Why?
|
| Walkers | 1 | 2010 | 3 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 40 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2017 | 27 | 0.080 |
Why?
|
| Patient Dropouts | 1 | 2011 | 50 | 0.080 |
Why?
|
| Comprehension | 1 | 2011 | 81 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2017 | 561 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2014 | 463 | 0.080 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 81 | 0.080 |
Why?
|
| Clinical Coding | 1 | 2010 | 14 | 0.080 |
Why?
|
| Urban Health | 1 | 2010 | 84 | 0.080 |
Why?
|
| Weight Gain | 1 | 2013 | 393 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 386 | 0.080 |
Why?
|
| Organizational Objectives | 3 | 2014 | 34 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 369 | 0.080 |
Why?
|
| Time | 1 | 2010 | 92 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 152 | 0.080 |
Why?
|
| MEDLINE | 1 | 2009 | 18 | 0.080 |
Why?
|
| Device Removal | 1 | 2012 | 225 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 905 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 321 | 0.080 |
Why?
|
| Phenotype | 3 | 2015 | 4497 | 0.080 |
Why?
|
| Caregivers | 3 | 2021 | 598 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 139 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 431 | 0.080 |
Why?
|
| Quality Control | 1 | 2009 | 116 | 0.070 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 19 | 0.070 |
Why?
|
| Solubility | 1 | 2009 | 117 | 0.070 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2008 | 3 | 0.070 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 38 | 0.070 |
Why?
|
| Body Weight | 1 | 2013 | 987 | 0.070 |
Why?
|
| Muscle, Skeletal | 3 | 2022 | 981 | 0.070 |
Why?
|
| Developing Countries | 1 | 2011 | 305 | 0.070 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2008 | 13 | 0.070 |
Why?
|
| Probenecid | 1 | 2008 | 5 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2016 | 1050 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2019 | 1223 | 0.070 |
Why?
|
| Genotype | 2 | 2013 | 2595 | 0.070 |
Why?
|
| Walking | 1 | 2010 | 230 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 71 | 0.070 |
Why?
|
| Informed Consent | 1 | 2011 | 351 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 226 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 341 | 0.070 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 35 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1722 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 230 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 235 | 0.070 |
Why?
|
| Creatine Kinase | 1 | 2007 | 61 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2007 | 65 | 0.060 |
Why?
|
| Professional Practice | 1 | 2007 | 39 | 0.060 |
Why?
|
| Medication Errors | 1 | 2009 | 192 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 475 | 0.060 |
Why?
|
| Societies, Scientific | 1 | 2006 | 25 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 138 | 0.060 |
Why?
|
| Americas | 1 | 2006 | 52 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 26 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2011 | 1483 | 0.060 |
Why?
|
| Body Composition | 1 | 2009 | 545 | 0.060 |
Why?
|
| Erythropoiesis | 1 | 2006 | 39 | 0.060 |
Why?
|
| Energy Intake | 1 | 2009 | 502 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2006 | 42 | 0.060 |
Why?
|
| Mental Health Services | 1 | 2009 | 285 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 50 | 0.060 |
Why?
|
| HIV Infections | 2 | 2014 | 2049 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2323 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2025 | 59 | 0.050 |
Why?
|
| Mortality, Premature | 2 | 2015 | 13 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 599 | 0.050 |
Why?
|
| Synovial Membrane | 1 | 2004 | 27 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2006 | 317 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 1239 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2003 | 32 | 0.050 |
Why?
|
| Orthopedics | 2 | 2017 | 78 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2024 | 192 | 0.050 |
Why?
|
| Myocarditis | 1 | 2005 | 122 | 0.050 |
Why?
|
| Lip | 1 | 2023 | 20 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 123 | 0.050 |
Why?
|
| Cognition | 1 | 2009 | 829 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2024 | 92 | 0.050 |
Why?
|
| Catastrophization | 1 | 2023 | 18 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 1 | 2024 | 378 | 0.050 |
Why?
|
| Neuroglia | 1 | 2025 | 224 | 0.050 |
Why?
|
| Proteome | 1 | 2025 | 285 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2024 | 288 | 0.050 |
Why?
|
| ROC Curve | 1 | 2004 | 613 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 344 | 0.050 |
Why?
|
| Receptors, Complement 3d | 1 | 2002 | 7 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2023 | 118 | 0.050 |
Why?
|
| Receptors, Complement 3b | 1 | 2002 | 13 | 0.050 |
Why?
|
| Wrist Joint | 1 | 2022 | 26 | 0.050 |
Why?
|
| Anemia | 1 | 2006 | 354 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 664 | 0.040 |
Why?
|
| Muscles | 1 | 2022 | 197 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 350 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 338 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2024 | 336 | 0.040 |
Why?
|
| Diphosphates | 1 | 2021 | 8 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 2730 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 1011 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 18 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 233 | 0.040 |
Why?
|
| Germany | 1 | 2020 | 61 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 33 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 429 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 393 | 0.040 |
Why?
|
| Social Stigma | 1 | 2020 | 82 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 463 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2550 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2002 | 451 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 523 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 268 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2024 | 1075 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1801 | 0.030 |
Why?
|
| Transcriptome | 1 | 2025 | 1103 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 24 | 0.030 |
Why?
|
| Colombia | 1 | 2017 | 51 | 0.030 |
Why?
|
| Mice | 3 | 2024 | 18301 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 713 | 0.030 |
Why?
|
| Magnesium Deficiency | 1 | 2017 | 10 | 0.030 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 21 | 0.030 |
Why?
|
| Djibouti | 1 | 2017 | 2 | 0.030 |
Why?
|
| Somalia | 1 | 2017 | 6 | 0.030 |
Why?
|
| Africa, Northern | 1 | 2017 | 10 | 0.030 |
Why?
|
| Hemochromatosis | 1 | 2017 | 44 | 0.030 |
Why?
|
| Middle East | 1 | 2017 | 36 | 0.030 |
Why?
|
| Vibration | 1 | 2016 | 29 | 0.030 |
Why?
|
| Pruritus | 1 | 2017 | 52 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 237 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 164 | 0.030 |
Why?
|
| Diuretics | 1 | 2017 | 159 | 0.030 |
Why?
|
| Fiducial Markers | 1 | 2016 | 3 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2016 | 6 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 2026 | 0.030 |
Why?
|
| Excipients | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3748 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2016 | 38 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2016 | 45 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 49 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 63 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 785 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 631 | 0.030 |
Why?
|
| Osteoporosis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Permeability | 1 | 2016 | 126 | 0.030 |
Why?
|
| Hawaii | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 361 | 0.030 |
Why?
|
| Sanitation | 1 | 2015 | 15 | 0.030 |
Why?
|
| California | 1 | 2015 | 127 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 291 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 174 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 116 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2015 | 26 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 224 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 49 | 0.030 |
Why?
|
| Genes, Plant | 1 | 2014 | 36 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2015 | 135 | 0.030 |
Why?
|
| Epidemics | 1 | 2014 | 58 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 187 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 109 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 298 | 0.020 |
Why?
|
| Developed Countries | 1 | 2013 | 43 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 383 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 480 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 2014 | 107 | 0.020 |
Why?
|
| Pregnancy | 2 | 2017 | 7512 | 0.020 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 6 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2025 | 4686 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 387 | 0.020 |
Why?
|
| Publishing | 1 | 2013 | 105 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 450 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1882 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 567 | 0.020 |
Why?
|
| Pediatric Obesity | 1 | 2017 | 419 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 29 | 0.020 |
Why?
|
| Occupational Health Services | 1 | 2011 | 5 | 0.020 |
Why?
|
| New York City | 1 | 2011 | 59 | 0.020 |
Why?
|
| Causality | 1 | 2011 | 89 | 0.020 |
Why?
|
| Urologic Diseases | 1 | 2011 | 42 | 0.020 |
Why?
|
| Joints | 1 | 2011 | 25 | 0.020 |
Why?
|
| Quarantine | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 604 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 66 | 0.020 |
Why?
|
| Moral Obligations | 1 | 2011 | 83 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2014 | 280 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 344 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 238 | 0.020 |
Why?
|
| Confidentiality | 1 | 2011 | 108 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 1282 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2011 | 208 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 358 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 514 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2011 | 398 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 970 | 0.010 |
Why?
|
| Breath Tests | 1 | 2006 | 182 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2006 | 286 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 826 | 0.010 |
Why?
|
| Drug Approval | 1 | 2003 | 48 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 2002 | 30 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1559 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 210 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1399 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4738 | 0.010 |
Why?
|